FBRX
Forte Biosciences, Inc.BS score 15.2LOWPHASE2 · mkt cap $470.7M · rev ttm $0
drug hypothesis
FB-401 modulates Unknown - target not specified in provided data to treat Mild to moderate atopic dermatitis (pediatric and adult).
moa:Unknown - MOA not specified in provided data
score breakdown
trial design0
base rate disconnect18
language red flags40
composite15.2
valuation analysis
market cap$470.7M
revenue ttm$0
phasePHASE2
historical base rate15%
disconnect ratio0.6x
lead trialNCT07205159
meta
cik0001419041
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Randomized, quadruple-blind, placebo-controlled Phase 2 trial enrolling 154 patients (2 years and older) with mild to moderate atopic dermatitis. Secondary endpoints include percent change in EASI.
primary endpoint:EASI 50 (50% improvement in Eczema Area and Severity Index) at 16 weeks
claimed differentiation
Unknown - differentiation claims not provided in filing data
language red flags
- Insufficient data provided to identify red flags - SEC filing business section appears incomplete or missing (only '  3' visible)
- Target, mechanism of action, and differentiation claims cannot be verified due to missing filing content
company-stated risks
- Risks not explicitly stated in provided data
upcoming catalysts
- 2021-07-14Trial completed - Primary completion date 2021-07-14